Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove Public Health Professionals
- Remove Information Professionals
- Remove English
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove Young Adults as Population Group
- Remove New Substance Users
- Remove People with Mental Health Problems as Population Group
- Remove Practitioner/Professional
- Remove Alcohol
- Remove Opioids or Opiates
- Remove Illegal Drugs
- Remove Marijuana
- Remove Heroin
- Remove Fentanyl
- Remove Illicit Stimulants
Main page content
Published: December 2021This resource provides information to primary care providers and practices on how to implement opioid use disorder treatment using buprenorphine. It identifies common barriers and strategies to overcome them. It documents step-by-step tactics to support buprenorphine implementation.
Published: August 2021The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: December 2019This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.